Clinical trial

Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone

NCT04296578

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2020-10-01

PhasePHASE1

Study timeline

Study start (estimated)2020-10-01Date precision: month

Registry last updated2021-08-12

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Castrate Resistant Prostate Cancerunresolved

Interventions

Abiraterone AcetateDRUG · verified · RxNorm: abiraterone acetate

Sodium SeleniteDRUG · verified · RxNorm: sodium selenite

PrednisoneDRUG · verified · RxNorm: prednisone

Sponsors & collaborators

Stanford Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04296578 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.